IPCALAB — Ipca Laboratories Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Ipca Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	46,487	54,200	58,298	62,443	77,050
Cost of Revenue
Gross Profit	27,090	33,861	34,487	35,130	46,027
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	39,354	41,224	47,714	55,448	69,495
Operating Profit	7,133	12,976	10,584	6,996	7,556
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	7,389	13,813	11,146	7,453	8,427
Provision for Income Taxes
Net Income After Taxes	6,036	11,411	8,898	4,919	5,292
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Net Income	6,063	11,400	8,841	4,713	5,474
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	6,063	11,400	8,841	4,713	5,474
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	24.7	45.7	35.2	18.2	25.9
Dividends per Share